沙利度胺联合干扰素在复发难治及体能、经济状况欠佳多发性骨髓瘤患者中的应用

摘要

Objective To preliminarily observe the clinical efficacy and safety of the thalidomide combined with interferon in treatment of recurrent or refractory patients with multiple myeloma (MM) in poor physical and economic conditions.Methods The clinical data of 9 MM patients who received the regimen of thalidomide combined with interferon in Henan Cancer Hospital from October 2011 to October 2015 were retrospectively analyzed.All 9 patients had poor physical and economic conditions,including 7 (77.8 ％) cases of recurrent or refractory and 2 cases newly diagnosed.The clinical efficacy and safety were evaluated.Results The efficacy of all patients were evaluable.There were 2 cases complete remission (CR),2 cases partial remission (PR),3 cases stable diseases (SD),and 2 cases progressive diseases (PD).The clinical benefit (CR + PR) rate was 44.4 ％.The main adverse reactions included the drug fever caused by interferon,perineurotoxicity and visceral neurotoxicity caused by thalidomide.No severe adverse reactions such as deep vein thrombosis occurred.Conclusions Thalidomide combined with interferon has a favorable effect on recurrent or refractory MM patients in poor physical or economic conditions,meanwhile,the adverse reactions of this regimen are tolerable for most patients.%目的 初步观察沙利度胺联合干扰素治疗多发性骨髓瘤(MM)的有效性及安全性,为复发难治及体能、经济状况欠佳的MM患者探索出一种经济、有效、安全、易耐受的治疗方案.方法 回顾性分析2011年10月至2015年10月在河南省肿瘤医院采用沙利度胺联合重组人干扰素α-1b方案治疗的9例MM患者的临床资料,9例患者体能、经济状况均欠佳,其中7例(77.8％)为复发、难治,2例为初诊.分析该治疗方案的有效性及安全性.结果 9例患者均可评价疗效.治疗后2例达完全缓解(CR),2例达部分缓解(PR),3例疾病稳定(SD),2例疾病进展(PD),总有效(CR+PR)率为44.4％(4/9).9例患者均可耐受该方案,主要不良反应为发热、周围神经毒性、便秘等,未出现严重心、肾、肝等重要脏器损伤.结论 沙利度胺联合干扰素方案对部分复发难治及体能、经济状况欠佳的MM患者安全、有效且治疗费用低,或可为该患者群体提供一种新的治疗选择.